Stem cells are the building blocks of your skin. They have a unique ability to replace damaged and diseased cells. As they divide, they can proliferate for long periods into millions of new skin cells.

As we age, our stem cells lose their potency. Your skins ability to repair itself just isnt what it used to be. The result can be fine lines, wrinkles, age spots, and sagging skin. But non-embryonic stem cells the same stem cells active early in life are highly potent.

Emerge Skin Cares Anti-Aging Stem Cell Skin Care Serum tap into the potency of these stem cells to renew skin.

Scientists at Emerge Labs Stem Cell Skin Care discovered that human non-embryonic stem cell extracts can renew skin by replacing old cells with healthy new ones. These stem cell extracts stimulate your own skins abilities to repair itself. And Emerge anti-aging stem cell serums were born. Where Stem Cells in Anti Aging Products Come From The first types of human stem cells to be studied by researchers were embryonic stem cells, donated from in vitro fertilization labs. But because creating embryonic stem cells involves the destruction of a fertilized human embryo, many people have ethical concerns about the use of such cells.

The non-embryonic stem cells in Lifeline stem cell serums are derived from unfertilized human oocytes (eggs) which are donated to ISCO from in vitro fertilization labs and clinics. Emerge Anti Aging Stem Cell Skin Care is Based On Proven Scientific Research Emerge Skin Cares exclusive anti-aging products are a combination of several discoveries and unique high-technology, patent-pending formulations.

PhytoCellTecMalus Domestica the first plant stem cell activefor skin stem cell protection with proven efficacy PhytoCellTec Malus Domestica is a liposomal preparation of apple stem cells developed by a novel, patent pending plant cell culture technology.

PhytoCellTec a novel plant cell culture technology has been invented to cultivate dedifferentiated callus cells from a rare Swiss apple. These apple stem cells are rich in epigenetic factors and metabolites, assuring the longevity of skin cells. PhytoCellTec Malus Domestica has been shown to protect skin stem cells and delay the senescence of hair follicles.

PhytoCellTec Malus Domestica provides a revolutionary anti-aging performance for real rejuvenation.

Claims with PhytoCellTec Malus Domestica Protects longevity of skin stem cells Delays senescence of essential cells Combats chronological aging

Continue reading here:
Stem Cell Skin Care - Science Meets Beauty

Physician First Choice Stem Cell Therapy (888) 828-4575
http://stemcelltreatmentclinic.com Physician First Choice offers US Board Certified stem cell doctors providing treatment in both the US and Mexico. Treatmen...

By: USPainNetwork

Original post:
Physician First Choice Stem Cell Therapy (888) 828-4575 - Video

Professor Arnold Caplan discusses mesenchymal stem cell therapy for multiple sclerosis
Professor Caplan is "The father of the mesenchymal stem cell (MSC)". In this clip, he describes a mouse experiment using human MSCs in a mouse model of MS. T...

By: http://www.cellmedicine.com

Follow this link:
Professor Arnold Caplan discusses mesenchymal stem cell therapy for multiple sclerosis - Video

Hitguj Stem Cell Therapy
For more info log on to http://www.24taas.com Like us on https://www.facebook.com/Zee24Taas Follow us on https://twitter.com/zee24taasnews.

By: Zee24Taas

See more here:
Hitguj Stem Cell Therapy - Video

Stem Cell Therapy in California Covered by Insurance (888) 828-4575
http://stemcelltherapyincalifornia.com TeleHealth offers stem cell therapy for arthritis, tendonitis, ligament injuries that is covered by insurance. This in...

By: USPainNetwork

Read more:
Stem Cell Therapy in California Covered by Insurance (888) 828-4575 - Video

Poway, California (PRWEB) September 12, 2013

The Arrow Group of Animal Hospitals, out of Glendale, Arizona and their 17 Phoenix Metro area veterinary hospitals have partnered with California based Vet-Stem, Inc., the leading Regenerative Veterinary Medicine company, to bring stem cell therapy to their patients. Dogs that are suffering pain or inflammation from osteoarthritis or polyarthritis, joint or ligament issues, or muscle injuries, can now receive stem cell therapy.

The Arrow Group of Animal Hospitals hosted Vet-Stems Corey Orava, DVM for a week of training sessions to help all of their staff learn the ins and outs of stem cell therapy. Veterinarians and technicians benefited from hands-on labs and a continuing education course that will help them bring the best care to their patients and pet owners. Under the mentorship of Dr. Orava Dobson Ranch Animal Hospital, Fletcher Heights Animal Hospital, Surprise Animal Hospital and Animal Hospital at Anthem were able to perform their debut stem cell therapy cases during their initial week of offering the new service.

The Arrow Group of Animal Hospitals is a co-operative group of 17 individual small animal hospitals around the valley that are proud to offer the highest quality veterinary care possible. The doctors and staff at each hospital strive to build a long term relationship with their client families and their pets, always making recommendations in the pets best health interest. The Arrow Group of Animal Hospitals offer complete veterinary care from wellness, to vaccines, spays and neuters, dental, surgical and now regenerative medicine. Their animal hospital locations can be easily found at http://www.azpetvet.com.

About Vet-Stem, Inc. Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem, Inc. pioneered the use of regenerative stem cells in veterinary medicine. The company holds exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells. In the last decade over 10,000 animals have been treated using Vet-Stem, Inc.s services, and Vet-Stem is actively investigating stem cell therapy for immune-mediated and inflammatory disease, as well as organ disease and failure. For more on Vet-Stem, Inc. and Veterinary Regenerative Medicine visit http://www.vet-stem.com or call 858-748-2004.

Read more:
The Arrow Group of Animal Hospitals in Central Arizona Partners with Vet-Stem, Inc. to Bring Stem Cell Therapy to ...

Interview with Mr. Rene Sarmiento of Powermax Re Stem Cell Therapy Summit Part 2

By: Fritz Capulong

Excerpt from:
Interview with Mr. Rene Sarmiento of Powermax Re Stem Cell Therapy Summit Part 2 - Video

Stem Cell Therapy - Cosmetic Surgery PH Beaufaces
Stem Cell Therapy at Beaufaces Cosmetic Surgery Center Manila, Philippines For more info visit http://www.cosmeticsurgeryph.com/ Or email us at info@cosmetic...

By: Cosmetic Surgery PH - Beaufaces

View original post here:
Stem Cell Therapy - Cosmetic Surgery PH Beaufaces - Video

2 months after stem cell therapy
Eveybody agrees that the therapy works. There is very big improvment the way Toby walks now.

By: Jacek Kozlowski

More here:
2 months after stem cell therapy - Video

What #39;s Stem Cell Therapy Dr Bill Johnson Has Answers
for more information go to... http://www.innovationstemcellcenter.com More useful info below... Drapeau #39;s theory that Adult Stem Cells are nothing less than the hum...

By: Mark Khan

Excerpt from:
What's Stem Cell Therapy Dr Bill Johnson Has Answers - Video

Stem Cell Therapy: Where #39;s the Evidence?
Dr. Tony Dans of the University of the Philippines College of Medicine discusses dilemmas in research and regulation of stem cell therapy in the Philippines....

By: Antonio Dans

See original here:
Stem Cell Therapy: Where's the Evidence? - Video

By: Jet Villa, InterAksyon.com August 13, 2013 8:42 AM

InterAksyon.com The online news portal of TV5

MANILA, Philippines - The Department of Health (DOH) has given all health facilities practicing stem cell therapy and companies importing and producing stem cell products untilAug. 31to apply for accreditation and product registration, respectively.

Nick Lutero, director of the DOH-Bureau of Health Facilities and Services, said it will be considered illegal for facilities to do stem cell procedures if they fail to comply with the requirement.

Papatigil namin ang pag-conduct ng therapy. For those still continuing to practice, I think we have sufficient laws, particularly on the illegal practice of medicine. They could be criminally liable, he said in a chance interview.

Lutero lamented that only five hospitals have applied for registration although the DOH had issued the guidelines on this since March.

We have done preliminary visits sa mga hospitals na ito at mukang based sa initial inspection, merong sufficient compliance sa mga facilities, he said.

Companies importing and producing stem cell products, on the other hand, should apply for registration with the Food and Drug Administration, an agency attached to the DOH.

Products that will not be applied for registration will also be considered illegal after the deadline.

Experimental treatment not for free

See original here:
DOH gives health facilities engaged in stem cell therapy until Aug. 31 to register

Advanced Topics - Stem Cell Therapy part 1

By: Jesse Matteson

Here is the original post:
Advanced Topics - Stem Cell Therapy part 1 - Video

Stem Cell Therapy - Amazing Breakthrough in Skin wrinkles treatment
Stem Cell Therapy is the newest bio-active topical cream that actually stimulates your own existing skin stem cells to grow smooth, supple, firm new skin. Fo...

By: Buystemcell.com.au

Read this article:
Stem Cell Therapy - Amazing Breakthrough in Skin wrinkles treatment - Video

NEW YORK, NY and PETAH TIKVA, ISRAEL--(Marketwired - Jul 29, 2013) - BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the European Commission has granted Orphan Drug Designation for NurOwn, the Company's stem cell therapy consisting of autologous bone marrow-derived mesenchymal stromal cells secreting neurotrophic factors, for the treatment of Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's Disease.NurOwn received Orphan Drug Designation from the Food and Drug Administration (FDA) in 2011.

Orphan drugs benefit from 10 years market exclusivity in the European Union (EU) after marketing approval. Additional benefits for sponsor companies include reduced fees for various centralized activities including applications for marketing authorization, inspections and protocol assistance, as well as possible eligibility for EU grants and other R&D-supporting initiatives.

BrainStorm is currently conducting a Phase IIa dose-escalating trial with 12 ALS patients at the Hadassah Medical Center in Jerusalem, Israel. The company anticipates launching a Phase II multi-center trial at three leading institutions in the United States towards the end of 2013, pending FDA approval.

About BrainStorm Cell Therapeutics, Inc.BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the company's website at http://www.brainstorm-cell.com.

Safe Harbor Statement - Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements.The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov.These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements.The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Read more from the original source:
BrainStorm's NurOwn Cell Therapy Receives Orphan Drug Designation in the European Union for ALS

TULSA, Oklahoma -

A controversial therapy that's not available for humans is being used on their pets. Stem cells are helping dogs and cats heal faster and get rid of pain as the animals get older.

Mandy Clinton loves her dog and she'd do just about anything for her.

"I've had her for 14 years. She's my homegirl," Clinton said about Libbi.

But Libbi has come up with a hitch in her giddy up. She tripped while walking up the stairs and tore her ACL.

Clinton was looking into surgery when she learned about stem cell therapy and its ability to help dogs heal faster and reduce pain.

"I had no idea. I had no idea. It blew my mind, but I've had Libbi for 14 years, and so I was ready to do it if it was possible," she said.

Dr. Joe Landers at Heritage Veterinary Hospital will be performing Libbi's surgery on Wednesday.

They'll harvest stem cells from Libbi's stomach, process and stimulate them, then implant the stem cells on her leg joint.

"If you've ever cut your skin, deeply with a knife or something, you've had stem cell repair," said Dr. Joe Landers, DVM.

Read more from the original source:
Oklahoma Veterinarian Offering Stem Cell Therapy For Aging Pets

#39;The results are profound #39;; Stem cell therapy used to treat animal ailments
#39;The results are profound #39;; Stem cell therapy used to treat animal ailments.

By: kgun9

Read more:
'The results are profound'; Stem cell therapy used to treat animal ailments - Video

FAQ1-Stem Cell Therapy
http://youtu.be/dJHlHBrmvrU Stem cell therapy has earned global fame for its proven ability to help sufferers of many diseases, with little ill effects or si...

By: Kerry Dean

Read the rest here:
FAQ1-Stem Cell Therapy - Video

DUBLIN, July 18, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/qc7zk2/stem_cell_therapy) has announced the addition of the "Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity" report to their offering.

(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity

Stem Cell Research in Asia-Pacific a Growth Engine for Region's Scientific Ambitions

The stem cell therapy market in Asia-Pacific is poised to offer significant contributions in the future, thanks to renewed interest by the respective governments of India, China, Japan, South Korea and Singapore to provide cures for a range of diseases, states a new report by healthcare experts GBI Research.

Stem cells are unique body cells that possess the ability to divide and differentiate into diverse cell types, and can be used to produce more stem cells. The use of adult stem cells has been successfully employed to treat bone and blood related disorders such as leukemia, through bone marrow transplants. Stem cell therapy is used to repair and regenerate the damaged tissue, though the actual mechanism of action is largely unknown.

The growth in the stem cell therapy market will not only provide treatment options but will also contribute significantly to the countries' Gross Domestic Product (GDP), with the President of South Korea only last year referring to stem cell research as a new growth engine for the nation's economy. In order to support the stem cell industry, regulatory guidelines in Asia-Pacific countries allow stem cell research, and this has led to its commercialization. India and South Korea are the leaders in the commercialization of stem cell therapy, with approved products for Acute Myocardial Infarction (AMI), osteoarthritis and anal fistula in Crohn's disease, amongst others. The countries allow the use of human embryonic stem cells and provide adequate funding support for the research.

Stem cell therapy is an emerging field, and a large amount of research is currently being carried out by institutions such as hospitals, universities and medical colleges. According to GBI Research's analysis of the stem cell therapy research in Asia-Pacific, 63% of pipeline molecules were being researched by academia. The emergence of institutional research has boosted stem cell discoveries, as companies can be put off conducting research due to uncertain therapeutic outcomes. China and Japan witness only a negligible industry presence in stem cell research, as academic institutions dominate - however in contrast, India has the presence of both industry and academia. The major institutions engaged in stem cell research in India are LV Prasad Eye Institute (LYPEI) for Limbal Stem Cell Technology (LSCT), and the Post Graduate Institute of Medical Education and Research (PGIMER) for stem cell therapy for type 2 diabetes mellitus.

The market is poised for significant growth in the future, due to the anticipated launch of JCR Pharmaceuticals' JR-031 in Japan in 2014, and FCB Pharmicell's Cerecellgram (CCG) in South Korea in 2015. GBI Research therefore predicts that the stem cell therapy market will grow in value from $545m in 2012 to $972m in 2018, at a Compound Annual Growth Rate (CAGR) of 10%.

See the original post here:
Stem Cell Therapy Market in Asia-Pacific to 2018

Manila, Philippines -- If she would have her way, Dr. Marita V.T. Reyes, Co-Chairperson of the Philippine Health Research Ethics Board (PHREB), yesterday said she would put a stop to the medical procedure of stem cell therapy.

Reyes delivered a paper yesterday on the topic, "Ethical Consideration In Stem Cell-based Therapy and Research-Poor Countries," on the last day of the 35th Annual Scientific Meeting of the Department of Science and Technology-National Academy of Science and Technology (DOST-NAST) at the historic landmark Manila Hotel.

Reyes acknowledged that there is a "standard" stem cell therapy treatment involving "hematopoietic disorders," such as "leukemia and lymphomas," through "bone marrow or cord blood transplant."

She, however, emphasized that this cannot be said yet in the cases of diseases of the heart, eyes, diabetes, stroke, spinal cord injury, Parkinson's, Alzheimer's, Lou Gehrig's (ALS), multiple sclerosis, cancer, and cartilage repair.

Stem cell therapy for these diseases, she stressed, should be stopped.

"If I have the power, I will say, 'stop this in the meantime, until the Food and Drug Administration (FDA) has come up with a quality assurance. Until the FDA is able to say that what you say is there, is there, we have no way of protecting our people," said Reyes, when asked about the ethics board's possible advice.

"So, as far as I am concerned, I would like the stem cell therapy, meaning for people who are saying they are using stem cell therapy, to stop, until we have set up very clear quality assurance (system)," the PHREB official said.

Stem cell therapy discussions resulted from the reported death of three Filipino politicians, and the complaint of a government official, after allegedly subjecting themselves from the controversial medical procedure.

Dr. Francisco Chung, Jr., of the Makati Medical Center (MMC), on the other hand, conceded that there are many stem cell procedures that are "experimental in nature."

"What we have approved clinically is bone marrow transplantation," he said, citing the approval of the United States Food and Drug Administration (USFDA).

Excerpt from:
Stop stem cell therapy – Doctor